12:00 AM
 | 
Jun 04, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Golvatinib: Phase I data

A dose-escalation Phase I trial in 34 patients with advanced solid tumors showed that once-daily 100-450 mg golvatinib produced 6 cases of stable disease. The MTD was once-daily 400 mg golvatinib. Dose-limiting toxicities (DLTs) included grade 3...

Read the full 163 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >